Abstract

AbstractWe present a study focused on the controlled fabrication of silver nanoparticles (AgNPs) through colloidal synthesis, employing dopamine as a reducing and capping agent. By manipulating the concentration of silver nitrate, the production of spherical AgNPs with distinct particle diameters (16, 24, 48, and 74 nm) was achieved. The investigation extended to the evaluation of AgNPs′ impact on human embryonic kidney cells, revealing a concentration‐dependent response. At lower AgNPs concentrations, cell viability remained nearly 100 %, progressively declining with rising AgNPs concentrations. Importantly, the cytotoxic thresholds observed were notably elevated, underscoring the relatively mild to moderate toxicity profile of the nanoparticles. Furthermore, the antimicrobial efficacy of these synthesized AgNPs was probed against E. coli and S. aureus bacterial strains. Notably, the AgNPs exhibited robust antimicrobial activity, with superior performance exhibited by smaller‐sized particles compared to larger ones. Impressively, the minimum inhibitory concentration reached as low as 3.5 μg/mL, indicating their potent antimicrobial potential. The achieved distinct particle diameters, concentration‐dependent cytotoxic responses, and potent antimicrobial efficacy against bacterial strains underscore the multifaceted potential of these nanoparticles. These findings contribute valuable insights for their application in diverse fields, from biomedicine to antimicrobial solutions.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.